A new class of K channel peptide toxin has been found in sea anemones. So far, four homologous 'short' toxins possessing 35-37 residues and 3 disulfide bonds have been isolated and sequenced. The two most thoroughly investigated members of this toxin group are ShK and BgK. The covalent structures of these toxins display no homology with the scorpion K toxins and their disulfide bonding pattern is also different. The NMR-derived solution structures of ShK and BgK toxins are similar in that two short alpha-helices are present, in contrast to the predominantly beta-sheet structures found in scorpion toxins. While BgK blocks Kv1.1,1.2 and 1.3 homomeric channels almost equipotently at 6-15 nM concentrations, ShK blocks Kv1.1 and 1.3 channels at very low (20-100 pM) concentrations and Kv1.2 at a much higher (>10 nM) concentration. The sea anemone peptides also interact with Kv1 heteromers present in rat brain membranes. Additionally, ShK has been shown to block intermediate conductance K(Ca) channels in lymphocytes and erythrocytes. Kv1.3 homomers are localized largely on the surfaces of T-lymphocytes; scorpion toxin blockade of these channels has been shown to inhibit proliferation of these cells in vitro and the development of delayed type hypersensitivity reaction and antibody formation in response to an allogeneic challenge in vivo. ShK toxin also inhibits in vitro lymphocyte proliferation in response to an antibody directed to a lymphocyte membrane antigen. The homomeric lymphocyte Kv1.3 and heteromeric brain Kv1 channel binding domains of ShK and BgK have been located by 'alanine scans' of analogs prepared by solid-phase peptide synthesis. Both toxins possess a receptor-binding 'hot spot' consisting of a sequentially contiguous Lys-Tyr diad on the second helical segment which spatially resembles a diad consisting of Lys27 and Tyr36 attached to a beta-sheet scaffold in charybdotoxin and related scorpion toxins. From analysis of the structural requirements for blocking Kv1.3 homomers and brain Kv1 heteromers, ShK analogs possessing even greater selectivity for the Kv1.3 channel have been designed. These peptides and smaller peptide-mimetic compounds incorporating the anemone toxin pharmacophore are being developed as potential immunosuppressant agents.
Introduction
Even after 15 years of clinical use, cyclosporin A is still the major immunosuppressant drug used to prevent rejection in organ transplant patients. While this powerful drug has greatly reduced rejection of transplanted organs, its substantial nephropathic, hypertensive, neurologic, diabetogenic and gastrointestinal side effects often limit its therapeutic efficacy [1, 2] . Thus, the search continues for additional, safer immunosuppressant drugs for this indication as well as for treatment of various auto-immume disorders such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and systemic lupus. An additional factor stimulating development of new immunosuppressants is that the increasing demand for organ transplants necessitating use of allografts from other species (such as the pig) will increase the probability of immune rejection. Tacrolimus (FK-506), though binding to a site different from cyclosporin, still works through an immunophilin-binding mechanism to inhibit calcineurin-mediated stimulation of cytokine transcription, and can cause side effects similar to cyclosporin [1] . Sirolimus (rapamycin) acts downstream from the initial steps of activation, inhibiting the lymphocyte proliferative response to the cytokine interleukin-2. Double and triple therapies have been instituted in an attempt to reduce the dosage of cyclosporin needed and still maintain immune tolerance [3] . In addition, depletion of recipient T lymphocytes before transplantation by administering polyclonal or monoclonal antibodies [4] or an immunotoxin [5] can greatly reduce the probability of an initial immune rejection. Other potential immunosuppression therapeutic targets include specific tyrosine kinases, protein kinase C isozymes, and sites controlling cytokine transcription [6, 7] . Finally, certain lymphocyte membrane ion channels, especially those for calcium (Ca) and potassium (K) ions, are potential therapeutic targets for inhibiting proliferation [8, 9] . This article will focus upon a relatively new immunosuppressant strategy, namely one of controlling proliferation by inhibiting T-lymphocyte K channels. This approach may eventually lead to new treatments for chronic autoimmune diseases such as multiple sclerosis, type 1 diabetes and systemic lupus in addition to treatment of organ transplantation patients.
To understand the rationale for this approach, consider the initial steps involved in elevation of the intracellular free calcium concentration in T lymphocytes, which stimulates the phosphatase calcineurin to trigger the transcription and secretion of certain cytokines (expecially interleukin-2) necessary for the cellular immune response. Elevation of intracellular calcium can occur as a result of several processes. Interaction of presented antigen to the T-cell receptor, through activation of a membrane bound phospholipase C, causes phosphoinositide (IP 3 )-mediated release of calcium into the cytoplas-
